{"schema_version":"secwatch.filing_event.v1","accession":"0001213037-26-000013","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2026-05-14T20:15:18+00:00","discovered_at":"2026-05-14T20:16:00.250105+00:00","generated_at":"2026-05-14T20:18:14.046261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib","bullets":["Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.","Completed End-of-Phase 2 FDA meeting; selected 30 mg onvansertib + FOLFIRI/bev for Phase 3.","Phase 2 CRDF-004: 30 mg arm ORR 72.2% vs SoC 43.2%; PFS HR 0.38 vs FOLFIRI/bev.","Appointed Mani Mohindru as permanent CEO, Josh Muntner as CFO, Ajay Aggarwal as COO.","Updated onvansertib data to be presented at ASCO 2026 rapid oral presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001213037-26-000013","json":"https://secwatch.observer/filing/0001213037-26-000013.json","markdown":"https://secwatch.observer/filing/0001213037-26-000013.md","text":"https://secwatch.observer/filing/0001213037-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/0001213037-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/crdf-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:18:14.046261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17a1232848b0b93fa4697f361120f65518292114","claim":"Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 14, 2026, Cardiff Oncology, Inc. issued a press release announcing a business update and financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/0001213037-26-000013-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}